Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets

Biogen (BIIB) PT Lowered to $304 at Stifel

February 3, 2022 11:12 AM EST

Stifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.

The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More

Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage

February 3, 2022 10:37 AM EST

Shares of Biogen (NASDAQ: BIIB) are down 3% in todays trading session after the company reported mixed results and guidance.

The biotechnology company reported EPS of $2.50, or $368.2 million, up from $2.33 per share, or $357.9 million, from the year-ago quarter. Adjusted EPS came in at $3.39, beating the FactSet consensus of $3.37.... More